title: Treatment of pediatric Burkitt lymphoma in Turkey.
abstract: This study aimed to assess the demographic data and treatment results of children who were diagnosed with Burkitt lymphoma and treated according to the Berlin-Frankfurt-Münster-95 (BFM) protocol in a single institution. A total of 48 patients (37 boys, 77%) with a median age of 8 years (range 2 to 16 years) at diagnosis, were evaluated. Primary tumor sites were abdomen (70.8%), head and neck (22.9%), peripheral lymph node (2%), bone (2%), and testis (2%). The 5-year overall survival (OS) and event-free survival (EFS) were 78.1±4% and 76.6±6%, respectively. In univariate analysis, hemoglobin level less than 10 g/dL, cerebrospinal fluid (CSF) positivity and dialysis requirement at diagnosis were found to be important reverse predictor factors for EFS (P; 0.001, 0.001, 0.004, respectively). In multivariate analysis, hemoglobin level less than 10 g/dL and dialysis at diagnosis were found to be important reverse predictor factors for EFS (P; 0.0001). The EFS of our patients was lower than the values achieved with BFM-95 protocol in other centers. This study provides evidence that low hemoglobin level, CSF positivity and dialysis at diagnosis were important predictor factors for EFS in children with Burkitt lymphoma.
authors.affiliation: Pediatric Hematology-Oncology, Cerrahpasa Faculty of Medicine, Marmara University Faculty of Medicine, Istanbul. tirajecelkan@yahoo.com
authors.forename: Tiraje Tülin
authors.initials: TT
authors.lastname: Celkan
authors.forename: Safa
authors.initials: S
authors.lastname: Bariş
authors.forename: Nihal
authors.initials: N
authors.lastname: Ozdemir
authors.forename: Alp
authors.initials: A
authors.lastname: Ozkan
authors.forename: Hilmi
authors.initials: H
authors.lastname: Apak
authors.forename: Omer
authors.initials: O
authors.lastname: Doğru
authors.forename: Serap
authors.initials: S
authors.lastname: Karaman
authors.forename: Aylin
authors.initials: A
authors.lastname: Canbolat
authors.forename: Mine
authors.initials: M
authors.lastname: Ozdil
authors.forename: Hilal
authors.initials: H
authors.lastname: Aki
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Adaletli
authors.forename: Sebuh
authors.initials: S
authors.lastname: Kurugoglu
authors.forename: Mehmet
authors.initials: M
authors.lastname: Hallac
authors.forename: Inci
authors.initials: I
authors.lastname: Yildiz
mesh_terms: D000008:Abdominal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D001215:Asparaginase / Q000008:administration & dosage / Q000009:adverse effects; D001706:Biopsy; D001859:Bone Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D002051:Burkitt Lymphoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D012307:Risk Factors; D016019:Survival Analysis; D013736:Testicular Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D014421:Turkey / Q000453:epidemiology; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D014750:Vincristine; D001215:Asparaginase; D011241:Prednisone; D003630:Daunorubicin